Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 4/20 | 0.40 |
| ▸ | CDK8 | P49336 | 4/20 | 0.40 |
| ▸ | HASPIN | Q8TF76 | 4/20 | 0.40 |
| ▸ | IKBKB | O14920 | 5/20 | 0.34 |
| ▸ | CHUK | O15111 | 3/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | PLK4 | O00444 | 1/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3016984 | 0.90 | CCNC (0.36) | CCNCCDK8HASPINNR3C1PGR | |
| SCHEMBL14822886 | 0.82 | CCNC (0.37) | CCNCCDK8HASPINIKBKBGRM2 | |
| SCHEMBL14666692 | 0.82 | CCNC (0.37) | CCNCCDK8HASPINIKBKBGRM2 | |
| SCHEMBL3027732 | 0.82 | DGAT1 (0.34) | CCNCCDK8HASPINNR3C1PGR | |
| SCHEMBL12081739 | 0.81 | NR3C2 (0.49) | CCNCCDK8HASPINIKBKBCHUK | |
| SCHEMBL3030374 | 0.81 | PGR (0.33) | CCNCCDK8HASPINNR3C1PGR | |
| SCHEMBL3025613 | 0.79 | MAPT (0.38) | CCNCCDK8HASPINNR3C1PGR | |
| SCHEMBL14666727 | 0.78 | NR3C1 (0.32) | CCNCCDK8HASPINNR3C1PGR | |
| SCHEMBL3028048 | 0.77 | NR3C1 (0.31) | CCNCCDK8HASPINNR3C1PGR | |
| SCHEMBL3030501 | 0.76 | FABP4 (0.36) | CCNCCDK8HASPINNR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2179994-B1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-8410166-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-8410166-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | TAKAHASHI YOICHI (JP) | 2013-01-31 | — | — | US | disclosed |
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | TAKAHASHI YOICHI (JP) | 2013-01-31 | — | — | US | disclosed |
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | TAKAHASHI YOICHI (JP) | 2013-01-31 | — | — | US | disclosed |
| US-8258131-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-04 | — | — | US | disclosed |
| US-8258131-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-08-12 | — | — | US | disclosed |
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-08-12 | — | — | US | disclosed |
| EP-2179994-A1 | FUSED BICYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | NR3C2, NR3C1, MC2R | CCNC 536/4885CDK8 1504/4885HASPIN 3463/4885 |
| US-20100204218-A1 | FUSED BICYCLIC COMPOUND | NR3C2, NR3C1, MC2R | CCNC 655/4885CDK8 2050/4885HASPIN 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.